Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. CA3083595 - METHODES D'ACTIVATION, DE MODIFICATION ET D'EXPANSION DE LYMPHOCYTES T GAMMA DELTA POUR LE TRAITEMENT DU CANCER ET DE MALIGNITES ASSOCIEES

Office Canada
Numéro de la demande 3083595
Date de la demande
Numéro de publication 3083595
Date de publication 31.05.2019
Type de publication A1
CIB
C12N 5/0783
CCHIMIE; MÉTALLURGIE
12BIOCHIMIE; BIÈRE; SPIRITUEUX; VIN; VINAIGRE; MICROBIOLOGIE; ENZYMOLOGIE; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE
NMICRO-ORGANISMES OU ENZYMES; COMPOSITIONS LES CONTENANT; CULTURE OU CONSERVATION DE MICRO-ORGANISMES; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE; MILIEUX DE CULTURE
5Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
07Cellules animales ou tissus animaux
071Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
078Cellules du sang ou du système immunitaire
0783Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
CPC
A61K 31/663
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K 31/675
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
675having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 38/2013
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins [IL]
2013IL-2
A61K 2035/122
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
122for inducing tolerance or supression of immune responses
A61K 2035/124
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
124the cells being hematopoietic, bone marrow derived or blood cells
Déposants IMMATICS US, INC.
Données relatives à la priorité 10 2017 127 984.9 27.11.2017 DE
62/591,041 27.11.2017 US
Titre
(EN) METHODS FOR ACTIVATING, MODIFYING AND EXPANDING GAMMA DELTA T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES
(FR) METHODES D'ACTIVATION, DE MODIFICATION ET D'EXPANSION DE LYMPHOCYTES T GAMMA DELTA POUR LE TRAITEMENT DU CANCER ET DE MALIGNITES ASSOCIEES
Abrégé
(EN)
The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of ?d T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of ?d T cells while depleting a- and/or ß-TCR positive cells. T cell populations comprising expanded ?d T cell and depleted or reduced a- and/or ß-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.

Également publié en tant que
EP2018830327
JP2020546300
MXMX/a/2020/005503